BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that on September 10-11, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 47,750 shares of common stock and 23,900 restricted stock units to 11 new employees under Mirum’s 2020 Inducement Plan.

Pharnext SA announces that the first patient has been enrolled in the PREMIER Open Label Extension study of PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A in the United States.

Lyell Immunopharma, Inc. announced that a poster describing the first-in-human Phase 1 trial design for LYL797, Lyell’s ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming for the treatment of solid tumors, is being presented today at the European Society for Medical Oncology Congress 2022 in Paris, France.

Shasqi announced it has opened the Phase 2 of their Phase 1/2a clinical study to further assess SQ3370 in anthracycline- naïve patients.

IRLAB Therapeutics IRLAB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that the last participating patient has been randomized and entered the ongoing Phase IIb study of lead candidate mesdopetam.

Amgen announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical development programs in patients with KRAS G12C-mutated colorectal cancer.

Regeneron Pharmaceuticals, Inc. announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.

Keros Therapeutics, Inc. announced that it presented preliminary clinical data from the Part 2 multiple ascending dose portion of its Phase 1 clinical trial of KER-012 in healthy postmenopausal women at the American Society of Bone and Mineral Research 2022 Annual Meeting on Sunday, September 11, 2022.

EpiVax, Inc. is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research to validate a method for immunogenicity risk assessment of host cell proteins for improving biosimilar product development and assessing product interchangeability.

Entera Bio Ltd. announced the details of “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass – Dose Proportional Absorption and Effect on Lumbar Spine BMD ” poster presentation at the American Society for Bone and Mineral Research Annual Meeting 2022, being held from September 9-12th in Austin, Texas.